Experimental CAR T-Cell therapy targets rare stiff person syndrome
NCT ID NCT06588491
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This phase 2 trial is testing a new treatment called KYV-101 for people with stiff person syndrome (SPS) that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and attack certain immune cells that may be causing the disease. The study will enroll 25 participants to see if the therapy can improve walking speed and reduce symptoms, while also monitoring for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STIFF PERSON SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KYV-101 (a type of CAR T-cell therapy made from the patient's own immune cells, targeting CD19)
What this could lead to
If successful, this could offer a new treatment option for people with stiff person syndrome that hasn't responded to other therapies, potentially improving mobility and reducing symptoms.
What could go wrong
This is an early-phase trial with only 25 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.